{
    "doi": "https://doi.org/10.1182/blood.V108.11.4640.4640",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=780",
    "start_url_page_num": 780,
    "is_scraped": "1",
    "article_title": "Abnormal Expression of TRAF Adapter Proteins in Waldenstrom\u2019s Macroglobulinemia. ",
    "article_date": "November 16, 2006",
    "session_type": "Abstracts Not Selected for Presentation",
    "topics": [
        "waldenstrom macroglobulinemia",
        "tumor necrosis factors",
        "cd40 antigens",
        "western blotting",
        "cd19 antigens",
        "cd40 ligand",
        "immunoglobulin m",
        "ligands",
        "low-grade lymphomas",
        "quantitative real-time polymerase chain reaction"
    ],
    "author_names": [
        "Xavier Leleu, MD",
        "Lian Xu",
        "Zachary R. Hunter",
        "Anne-Sophie Moreau, MD",
        "Xiaoying Jia",
        "Garrett O\u2019Sullivan",
        "Vinod Bakthavachalam",
        "Allen W. Ho",
        "Evdoxia Hatjiharissi, MD",
        "Hai T. N\u2019Go",
        "Daniel D. Santos, MD",
        "Kelly O\u2019Connor",
        "Robert Manning",
        "Jacob Soumerai",
        "Christopher Patterson",
        "Irene M. Ghobrial, MD",
        "Steven P. Treon, MD"
    ],
    "author_affiliations": [
        [
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ],
        [
            "Bing Center for Waldenstrom\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA",
            "Service des Maladies du Sang et Laboratoire d\u2019Immunologie, CHRU, Lille, USA"
        ]
    ],
    "first_author_latitude": "50.6108999",
    "first_author_longitude": "3.0347031",
    "abstract_text": "Background: Waldenstro\u0308m\u2019s Macroglobulinemia (WM) is an incurable low-grade lymphoplasmacytic lymphoma with as yet unknown genetic basis for its pathogenesis. Several TNF family members (CD40L, APRIL and BAFF/BLYS) are known to regulate WM growth and survival. TRAFs are a novel family of adapter proteins that facilitate pro-apoptotic (TACI) or pro-survival/differentiation (CD40, BAFFR, BCMA) receptor signaling mediated by TNF family ligands. Therefore, understanding the TRAF system in WM may yield important clues about WM growth and survival. Methods: WM cell lines (BCWM.1 and WSU-WM), IgM secreting low-grade lymphoma cell lines (MEK1, RL, Namalwa), and primary bone marrow CD19 + selected lymphoplasmacytic cells (LPC) from 20 WM patients and 6 healthy donors were evaluated for TRAF (TRAF 2, 3, 5, 6) expression using semi quantitative RT-PCR and/or western blot analysis. Results: The TNF familiy receptors CD40, BAFFR, BCMA, and TACI were expressed in all cell lines tested as well as in CD19+ selected LPC from WM patients and healthy donors. Moreover, TRAF 2, 3, 5, 6 were expressed in all cell lines by both RT-PCR and western blot analysis. In contrast, we observed loss or abnormally low expression of both TRAF 2 and 5 in 6/20 (30%) patients, whilst TRAF 3 was absent or abnormally low in 3/30 (15%) patients. TRAF 6 was expressed in all patients. Among healthy donors, we observed expression of all TRAF adapter proteins. Conclusion: Up to one third of WM patients demonstrate loss of TRAF 2 and 5 adapter proteins which facilitate signaling through the pro-apoptotic receptor TACI. Ongoing studies including gene sequencing and siRNA knockdown models are delineating a role for TRAF loss in the pathogenesis of WM."
}